Similar articles

• [New, in Austria registered specialty drugs. Normoxin (moxonidine)].

  Kögler H, Raneburger J. Kögler H, et al. Wien Klin Wochenschr. 1993;105(3):94-6. Wien Klin Wochenschr. 1993. PMID: 8447129 Review. German. No abstract available.
• Effective antihypertensive therapy: blood pressure control with moxonidine.

  Prichard BN, Graham BR. Prichard BN, et al. J Cardiovasc Pharmacol. 1996;27 Suppl 3:S38-48. J Cardiovasc Pharmacol. 1996. PMID: 8872298 Review.
• Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.

  Prichard BN, Owens CW, Graham BR. Prichard BN, et al. J Hum Hypertens. 1997 Aug;11 Suppl 1:S29-45. J Hum Hypertens. 1997. PMID: 9321737 Review.
• Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.

  Sharma AM, Wagner T, Marsalek P. Sharma AM, et al. J Hum Hypertens. 2004 Sep;18(9):669-75. doi: 10.1038/sj.jhh.1001676. J Hum Hypertens. 2004. PMID: 15269705
• Moxonidine for hypertension.

  [No authors listed] [No authors listed] Drug Ther Bull. 1997 May;35(5):33-6. Drug Ther Bull. 1997. PMID: 9282418 Review.